Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
ESMO 2024 – degraders disappoint again
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
ESMO 2024 preview – Astellas’s KRAS degrader disappoints
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
EHA 2024 – Nurix and BeiGene’s degraders shine
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
